Imaging Tumor Sensitivity to a Bioreductive Prodrug: Two for the Price of One!

被引：7

作者：

Brown, J. Martin ^{[1
]}

机构：

[1] Stanford Univ, Stanford Med Ctr, CCSR, Dept Radiat Oncol, Stanford, CA 94305 USA

来源：

CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 06期

关键词：

RADIATION ONCOLOGY GROUP; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; ADVANCED HEAD; TROG; 02.02; TIRAPAZAMINE; HYPOXIA; RADIOTHERAPY;

D O I：

10.1158/1078-0432.CCR-11-3267

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypoxia is an important characteristic of many solid tumors and has a major negative effect on treatment response. A way to combat this effect is with drugs called "bioreductive prodrugs" or "hypoxic cytotoxins," which are metabolized under hypoxia to toxic species. However, the patients with hypoxic tumors need to be identified. Clin Cancer Res; 18(6); 1487-9. (C)2012 AACR.

引用

收藏

页码：1487 / 1489

页数：3

相关论文

共 8 条

[1] Exploiting tumour hypoxia in cancer treatment [J].

Brown, JM ;

William, WR .

NATURE REVIEWS CANCER, 2004, 4 (06) :437-447

[2] Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors [J].

Hicks, Kevin O. ;

Siim, Bronwyn G. ;

Jaiswal, Jagdish K. ;

Pruijn, Frederik B. ;

Fraser, Annie M. ;

Patel, Rita ;

Hogg, Alison ;

Liyanage, H. D. Sarath ;

Dorie, Mary Jo ;

Brown, J. Martin ;

Denny, William A. ;

Hay, Michael P. ;

Wilson, William R. .

CLINICAL CANCER RESEARCH, 2010, 16 (20) :4946-4957

[3] 18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer [J].

Komar, Gaber ;

Seppaenen, Marko ;

Eskola, Olli ;

Lindholm, Paula ;

Groenroos, Tove J. ;

Forsback, Sarita ;

Sipilae, Hannu ;

Evans, Sydney M. ;

Solin, Olof ;

Minn, Heikki .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (12) :1944-1951

[4] Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - A systematic review and meta-analysis [J].

Overgaard, Jens .

RADIOTHERAPY AND ONCOLOGY, 2011, 100 (01) :22-32

[5] Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 [J].

Peters, Lester J. ;

O'Sullivan, Brian ;

Giralt, Jordi ;

Fitzgerald, Thomas J. ;

Trotti, Andy ;

Bernier, Jacques ;

Bourhis, Jean ;

Yuen, Kally ;

Fisher, Richard ;

Rischin, Danny .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) :2996-3001

[6] Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine:: A substudy of Trans-Tasman Radiation Oncology Group study 98.02 [J].

Rischin, D ;

Hicks, RJ ;

Fisher, R ;

Binns, D ;

Corry, J ;

Porceddu, S ;

Peters, LJ .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2098-2104

[7] Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group [J].

Rischin, Danny ;

Peters, Lester J. ;

O'Sullivan, Brian ;

Giralt, Jordi ;

Fisher, Richard ;

Yuen, Kally ;

Trotti, Andy ;

Bernier, Jacques ;

Bourhis, Jean ;

Ringash, Jolie ;

Henke, Michael ;

Kenny, Lizbeth .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) :2989-2995

[8] The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia [J].

Wang, Jingli ;

Foehrenbacher, Annika ;

Su, Jiechuang ;

Patel, Rita ;

Hay, Michael P. ;

Hicks, Kevin O. ;

Wilson, William R. .

CLINICAL CANCER RESEARCH, 2012, 18 (06) :1684-1695